Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Capdevila, J.
  • Hernando, J.
  • Teule, A.
  • Lopez, C.
  • Garcia-Carbonero, R.
  • Benavent, M.
  • Custodio, A.
  • Garcia-Alvarez, A.
  • Cubillo, A.
  • Alonso, V.
  • Carmona-Bayonas, A.
  • Alonso-Gordoa, T.
  • Crespo, G.
  • Jimenez-Fonseca, P.
  • Blanco, M.
  • Viudez, A.
  • La Casta, A.
  • Sevilla, I.
  • Llanos, M.
  • Landolfi, S.
  • Nuciforo, P.
  • Manzano, J. L.

Grupos

Abstract

Single immune checkpoint blockade in advanced neuroendocrine neoplasms (NENs) shows limited efficacy; dual checkpoint blockade may improve treatment activity. Dune (NCT03095274) is a non-randomized controlled multicohort phase II clinical trial evaluating durvalumab plus tremelimumab activity and safety in advanced NENs. This study included 123 patients presenting between 2017 and 2019 with typical/atypical lung carcinoids (Cohort 1), G1/2 gastrointestinal (Cohort 2), G1/2 pancreatic (Cohort 3) and G3 gastroenteropancreatic (GEP) (Cohort 4) NENs; who progressed to standard therapies. Patients received 1500 mg durvalumab and 75 mg tremelimumab for up to 13 and 4 cycles (every 4 weeks), respectively. The primary objective was the 9-month clinical benefit rate (CBR) for cohorts 1-3 and 9-month overall survival (OS) rate for Cohort 4. Secondary endpoints included objective response rate, duration of response, progression-free survival according to irRECIST, overall survival, and safety. Correlation of PD-L1 expression with efficacy was exploratory. The 9-month CBR was 25.9%/35.5%/25% for Cohorts 1, 2, and 3 respectively. The 9-month OS rate for Cohort 4 was 36.1%, surpassing the futility threshold. Benefit in Cohort 4 was observed regardless of differentiation and Ki67 levels. PD-L1 combined scores did not correlate with treatment activity. Safety profile was consistent with that of prior studies. In conclusion, durvalumab plus tremelimumab is safe in NENs and shows modest survival benefit in G3 GEP-NENs; with one-third of these patients experiencing a prolonged OS.

© 2023. The Author(s).

Datos de la publicación

ISSN/ISSNe:
2041-1723, 2041-1723

Nature Communications  NATURE PORTFOLIO

Tipo:
Article
Páginas:
2973-2973
PubMed:
37221181
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
4,846 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 55

Citas Recibidas en Scopus: 44

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • PHASE-II; TUMORS; TRIAL; CHEMOTHERAPY; NIVOLUMAB; BEVACIZUMAB; IPILIMUMAB; GUIDELINES; EVEROLIMUS; SURVIVAL

Campos de Estudio

Cita

Compartir